TY - JOUR
T1 - Association of schizophrenia polygenic risk score with data-driven cognitive subtypes
T2 - A six-year longitudinal study in patients, siblings and controls
AU - Habtewold, Tesfa Dejenie
AU - Liemburg, Edith J.
AU - Islam, Md Atiqul
AU - de Zwarte, Sonja M. C.
AU - Boezen, H. Marike
AU - Luykx, Jurjen J.
AU - Rutten, Batt P. F.
AU - van Winkel, Ruud
AU - van Amelsvoort, Therese
AU - Bartels-Velthuis, Agna A.
AU - Cahn, Wiepke
AU - de Haan, Lieuwe
AU - Kahn, Rene S.
AU - Schirmbeck, Frederike
AU - Simons, Claudia J. P.
AU - van Os, Jim
AU - Bruggeman, Richard
AU - Alizadeh, Behrooz Z.
AU - Genetic Risk and Outcome of Psychosis (GROUP) Investigators
N1 - Funding Information:
Tesfa Dejenie is supported by the scholarship for a PhD from the University of Groningen, Groningen, the Netherlands. This research was supported by Geestkracht programme of the Dutch Health Research Council (Zon-Mw) (10-000-1001), and matching funds from participating pharmaceutical companies (Lundbeck; AstraZeneca; Eli Lilly and Janssen Cilag) and, universities and mental health care organizations (Amsterdam: Academic Psychiatric Centre of the Academic Medical Center and the mental health institutions: GGZ Ingeest; Arkin, Dijk en Duin; GGZ Rivierduinen; Erasmus Medical Centre and GGZ Noord Holland Noord. Groningen: University Medical Center Groningen and the mental health institutions: Lentis, GGZ Friesland; GGZ Drenthe; Dimence; Mediant; GGNet Warnsveld; Yulius Dordrecht and Parnassia psycho-medical center The Hague. Maastricht: Maastricht University Medical Centre and the mental health institutions: GGZ Eindhoven en De Kempen; GGZ Breburg; GGZ Oost-Brabant; Vincent van Gogh voor Geestelijke Gezondheid; Mondriaan; Virenze riagg; Zuyderland GGZ; MET ggz; Universitair Centrum Sint-Jozef Kortenberg; CAPRI University of Antwerp; PC Ziekeren Sint-Truiden; PZ Sancta Maria Sint-Truiden; GGZ Overpelt and OPZ Rekem. Utrecht: University Medical Center Utrecht and the mental health institutions: Altrecht; GGZ Centraal and Delta). The sponsors have no role in designing of the study, the collection, analysis, and interpretation of data, the writing of the report and the decision to submit the paper for publication.
Funding Information:
Tesfa Dejenie is supported by the scholarship for a PhD from the University of Groningen, Groningen, the Netherlands. This research was supported by Geestkracht programme of the Dutch Health Research Council (Zon-Mw) ( 10-000-1001 ), and matching funds from participating pharmaceutical companies ( Lundbeck ; AstraZeneca ; Eli Lilly and Janssen Cilag ) and, universities and mental health care organizations (Amsterdam: Academic Psychiatric Centre of the Academic Medical Center and the mental health institutions: GGZ Ingeest ; Arkin, Dijk en Duin; GGZ Rivierduinen ; Erasmus Medical Centre and GGZ Noord Holland Noord . Groningen: University Medical Center Groningen and the mental health institutions: Lentis, GGZ Friesland; GGZ Drenthe; Dimence; Mediant; GGNet Warnsveld; Yulius Dordrecht and Parnassia psycho-medical center The Hague. Maastricht: Maastricht University Medical Centre and the mental health institutions: GGZ Eindhoven en De Kempen; GGZ Breburg; GGZ Oost-Brabant; Vincent van Gogh voor Geestelijke Gezondheid; Mondriaan; Virenze riagg; Zuyderland GGZ; MET ggz; Universitair Centrum Sint-Jozef Kortenberg; CAPRI University of Antwerp; PC Ziekeren Sint-Truiden; PZ Sancta Maria Sint-Truiden; GGZ Overpelt and OPZ Rekem. Utrecht: University Medical Center Utrecht and the mental health institutions: Altrecht; GGZ Centraal and Delta). The sponsors have no role in designing of the study, the collection, analysis, and interpretation of data, the writing of the report and the decision to submit the paper for publication.
Publisher Copyright:
© 2020 The Authors
PY - 2020/9
Y1 - 2020/9
N2 - Cross-sectional studies have shown that the polygenic risk score for schizophrenia (PRSSCZ) may influence heterogeneity in cognitive performance although evidence from family-based longitudinal study is limited. This study aimed to identify trajectories of cognitive function and assess whether the PRSSCZ is associated with baseline cognitive performance and predicted six-year trajectories. We included 1119 patients with a schizophrenia spectrum disorder, and 1059 unaffected siblings and 586 unrelated controls who are eligible at baseline. Genotype data were collected at baseline, whereas clinical and sociodemographic data were collected at baseline, three and six years. Group-based trajectory modeling was applied on a weighted standardized composite score of general cognition to unravel cognitive subtypes and explore trajectories over time. We followed a standard procedure to calculate the polygenic risk score. A random-effects ordinal regression model was used to investigate the association between PRSSCZ and cognitive subtypes. Five cognitive subtypes with variable trajectories were found in patients, four in siblings and controls, and six in all combined samples. PRSSCZ significantly predicted poor cognitive trajectories in patients, siblings and all samples. After Bonferroni correction and adjustment for non-genetic factors, only the results in all combined sample remained significant. Cognitive impairment in schizophrenia is heterogeneous and may be linked with high PRSSCZ. Our finding confirmed at least in all combined samples the presence of genetic overlap between schizophrenia and cognitive function and can give insight into the mechanisms of cognitive deficits. (C) 2020 The Authors. Published by Elsevier B.V.
AB - Cross-sectional studies have shown that the polygenic risk score for schizophrenia (PRSSCZ) may influence heterogeneity in cognitive performance although evidence from family-based longitudinal study is limited. This study aimed to identify trajectories of cognitive function and assess whether the PRSSCZ is associated with baseline cognitive performance and predicted six-year trajectories. We included 1119 patients with a schizophrenia spectrum disorder, and 1059 unaffected siblings and 586 unrelated controls who are eligible at baseline. Genotype data were collected at baseline, whereas clinical and sociodemographic data were collected at baseline, three and six years. Group-based trajectory modeling was applied on a weighted standardized composite score of general cognition to unravel cognitive subtypes and explore trajectories over time. We followed a standard procedure to calculate the polygenic risk score. A random-effects ordinal regression model was used to investigate the association between PRSSCZ and cognitive subtypes. Five cognitive subtypes with variable trajectories were found in patients, four in siblings and controls, and six in all combined samples. PRSSCZ significantly predicted poor cognitive trajectories in patients, siblings and all samples. After Bonferroni correction and adjustment for non-genetic factors, only the results in all combined sample remained significant. Cognitive impairment in schizophrenia is heterogeneous and may be linked with high PRSSCZ. Our finding confirmed at least in all combined samples the presence of genetic overlap between schizophrenia and cognitive function and can give insight into the mechanisms of cognitive deficits. (C) 2020 The Authors. Published by Elsevier B.V.
KW - Cognition
KW - Cognitive trajectory
KW - Heterogeneity
KW - Polygenic risk score
KW - Psychosis
KW - Schizophrenia
KW - LONG-TERM TRAJECTORIES
KW - NEGATIVE SYMPTOMS
KW - RELIABILITY
KW - CONSORTIUM
KW - NEUROCOGNITIVE ENDOPHENOTYPES
KW - SOCIAL-ADJUSTMENT
KW - GENETIC OVERLAP
KW - INTERMEDIATE PHENOTYPES
KW - PSYCHOTIC DISORDERS
KW - STRUCTURED INTERVIEW
U2 - 10.1016/j.schres.2020.05.020
DO - 10.1016/j.schres.2020.05.020
M3 - Article
C2 - 32631699
SN - 0920-9964
VL - 223
SP - 135
EP - 147
JO - Schizophrenia Research
JF - Schizophrenia Research
ER -